ALK and non-small cell lung carcinoma: With a 3-year PFS rate of 63.5%, the results from the CROWN study indicated that lorlatinib has the potential to ultimately exceed 60 months in median PFS as a first-line treatment in patients with ALK positive NSCLC (19).